Rajeev Patel, MD
Internal Medicine · Texarkana, TXNPI 1114173754
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,052 of the $8,364 with a category attached, or 60.4%. 30 manufacturers reported payments, led by Abbott at 56.7% of the total. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $50.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- AstraZeneca$521
- Amgen$352
- Boston Scientific$347
- E.r. Squibb & Sons, L.L.C.$299
- Johnson & Johnson$220
- plus $2K from 24 others
Across 18 payments — averaging $5356.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$96K
What the payments were for
- Travel & lodging$3,15838%
- Food & beverage$5,05260%
- Education$1542%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 34 | $4,739 |
| AstraZeneca | 16 | $521 |
| Amgen | 10 | $352 |
| Boston Scientific | 6 | $347 |
| E.r. Squibb & Sons, L.L.C. | 14 | $299 |
| Johnson & Johnson | 12 | $220 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $219 |
| Novartis | 4 | $165 |
| Shockwave Medical, Inc | 1 | $158 |
| Pfizer | 8 | $140 |
| Esperion Therapeutics, Inc. | 3 | $133 |
| Atricure, Inc. | 6 | $130 |
| Amarin Pharma, Inc. | 2 | $128 |
| Merck | 7 | $111 |
| Medtronic | 1 | $79 |
| Philips North America LLC | 4 | $76 |
| Daiichi Sankyo Inc. | 3 | $67 |
| Lexicon Pharmaceuticals, Inc. | 3 | $66 |
| Scpharmaceuticals Inc. | 3 | $61 |
| Boehringer Ingelheim | 3 | $60 |
| Baxter Healthcare | 2 | $58 |
| Inspire Medical Systems, Inc. | 1 | $42 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $39 |
| Bayer | 2 | $36 |
| Actelion Pharmaceuticals US, Inc. | 1 | $34 |
| Aroa Biosurgery Incorporated | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Heartflow, Inc. | 1 | $17 |
| Biosense Webster, Inc. | 1 | $13 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$2,987
- TRICLIP$821
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$158
- MitraClip System$136
- WATCHMAN Access System$126
- FARXIGA$125
- Vascepa$122
- Repatha$122
- ENTRESTO$112
- ELIQUIS$107
How this compares
$8,364 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 179 | $247,421 |
| EntrestoSacubitril/Valsartan | 79 | $113,628 |
| JardianceEmpagliflozin | 29 | $41,860 |
| FarxigaDapagliflozin Propanediol | 35 | $39,368 |
| XareltoRivaroxaban | 30 | $32,767 |
| BrilintaTicagrelor | 26 | $21,513 |
| Atorvastatin Calcium | 389 | $5,167 |
| Metoprolol Succinate | 280 | $5,029 |
| Rosuvastatin Calcium | 115 | $3,557 |
| Ezetimibe | 85 | $2,986 |
| Losartan Potassium | 183 | $2,086 |
| Carvedilol | 114 | $848 |
| ClopidogrelClopidogrel Bisulfate | 55 | $737 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 30 | $732 |
| Spironolactone | 46 | $620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $140 | $247,421179 claims |
| NovartisEntresto | $165 | $113,62879 claims |
| AstraZenecaFarxiga, Brilinta | $521 | $60,88061 claims |
| Boehringer IngelheimJardiance | $60 | $41,86029 claims |
| Johnson & JohnsonXarelto | $220 | $32,76730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Texarkana
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.